Research has played a vital role in changing the face of the medical field. From untreatable diseases to highly contagious diseases, research made wondrous achievements and solved the previously unsolvable. The research on HIV has also provided us with life-saving treatments like a prophylaxis from HIV. The WHO (World Health Organization) convened a meeting in… Continue reading
Posts Tagged → #HIVAIDS
HIV PEP Can Save Rape Victims In India; Chem Sex Has Impact On PEP and Condom Use
HIV PEP Can Save Rape Victims In India A 3-day movement was started in Mumbai, India, to spread awareness of the use of HIV PEP as a preventive measure for rape victims from getting infected by the HIV virus. Several medical professionals and institutions took part in this movement. Although it is an established fact that… Continue reading
HIV PEP Drugs: Viread® (tenofovir) nucleotide analogue reverse transcriptase inhibitor (NRTI)
Tenofovir (Viread®) was invented by Antonín Holý from at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic and patented in 1984, making this one of the earliest antiviral drugs. In collaboration with Gilead Sciences and the University of California, it was developed into its current form and was approved for… Continue reading
HIV PEP drugs: Emtriva® (emtricitabine) reverse transcriptase inhibitor
Emtricitabine was developed as a combined effort between Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi, and Dr. Woo-Baeg Choi at Emory university and was patented by Emory through Triangle Pharmaceuticals under the trade name of Emtriva® in 1996. Triangle Pharmaceuticals has been owned by Gilead Sciences since 2003. Emtriva®™ targets the HIV protein reverse transcriptase. By inhibiting… Continue reading
HIV PEP drugs: Kaletra® (lopinavir/ritonavir) viral protease inhibitors
The HIV PEP designer drug Kaletra® (LPV/r) contains the two HIV viral protease inhibitors lopinavir (LPV) and ritonavir (RTV) [Norvir®]. Developed by Abbott laboratories in 2000, it is referred to as a designer drug as it was specifically formulated based on X-ray crystallography structures to specifically target the HIV protease. Both lopinavir and ritonavir inhibit the… Continue reading
HIV PEP: Frequently asked questions
What is PEP? PEP stands for Post-Exposure Prophylaxis and is a combination of drugs (usually lopinavir/ritonavir, emtricitabine and tenofovir) that will prevent replication of the HIV virus long enough for your body to clear it. How does PEP work? HIV PEP uses a three-pronged attack, aiming at elements of the virus essential for replication and… Continue reading
End users’ perspective of HIV PEP
HIV PEP has been a revolutionary treatment that has prevented many who have been exposed to the HIV virus from getting infected. Information, news, scientific findings, views and recommendations have always been coming from healthcare institutions and scientific bodies, but seldom do we get the chance to know views and experiences of end-users who are prescribing PEP… Continue reading
A systemic review for choice of HIV PEP treatment on Children with HIV exposure
The Human Immunodeficiency Virus (HIV) is not an adult-only disease but is also known to infect infants and children. The common causes of HIV infections in children are usually accidental needle stick injuries, premastication and sexual assault. Guidelines for adults recommend a base of tenofovir with lamivudine (3TC)/emtricitabine (FTC) and a third drug which is either… Continue reading
HIV Pre-exposure Prophylaxis, Post-Exposure Prophylaxis and Early Treatment: An Integration
With advancements in the field of research and scientific probing, we are continuously getting better treatments and vaccinations for different diseases. Although, there are currently no vaccines which can prevent HIV, scientists have been able to formulate the next best thing – HIV Pre-exposure Prophylaxis (PrEP). A report by the Center of Diseases, Control and… Continue reading
Adherence to HIV post-exposure Prophylaxis and its Side Effects: A study from Ghana
HIV holds a great threat to health care workers as constant exposure may lead to accidental HIV infection in previously un-infected individuals. A timely treatment of HIV Post-exposure Prophylaxis (PEP) is a prevention therapy that has been proven to be highly effective in protecting against occupational HIV infection. Due to its potential toxicities though, a… Continue reading